90,000 Patients Are Waiting for a Kidney. A 69-Edit Pig Organ and a New Antibody Just Produced Zero Rejections After Six Months.
eGenesis's CRISPR-edited pig kidney and Eledon's tegoprubart antibody are already combined in the same transplant protocol, and the Phase 2 data just dropped: 21% better kidney function than tacrolimus at 18 months, zero biopsy-proven rejections after month six, and side-effect rates that make the 30-year-old standard of care look primitive. Meanwhile, 90,000 Americans burn $8.9 billion a year on dialysis, waiting for a human organ that statistically will not arrive in time.
Last week, at the American Transplant Congress in Boston, Eledon Pharmaceuticals presented long-term follow-up data from its Phase 2 BESTOW trial of tegoprubart, an anti-CD40L antibody designed to replace tacrolimus as the cornerstone of transplant immunosuppression. Two days earlier, a team from Massachusetts General Hospital and eGenesis published a Nature Communications paper identifying exactly which of their pig kidney's 69 gene edits mattered most for keeping the human immune system at bay. Neither group planned the timing, and it does not matter. The convergence is real, and the data is starting to compound.
Two Problems, One Operating Room
Xenotransplantation has always faced a two-front war. Engineer the donor organ to look less foreign. Suppress the recipient's immune system enough to accept it. Both are hard problems that would each take decades to solve independently. For decades, both fronts moved slowly, independently, and with little coordination between the genetics labs and the immunology clinics. Now they are colliding inside the same patients.
On the organ side, eGenesis's EGEN-2784 kidney carries 69 genomic modifications: knockout of the three carbohydrate xenoantigens (GGTA1, B4GALNT2, CMAH) that trigger hyperacute rejection, inactivation of porcine endogenous retroviruses, and insertion of seven human transgenes. Among those seven, the new Nature Communications data identifies two transgenes as decisive: TNFAIP3 (suppresses NF-κB signaling) and HMOX1 (protects against oxidative stress). In nonhuman primates, kidneys carrying both showed significantly reduced T-cell infiltration and prolonged survival.
On the immunosuppression side, tegoprubart targets CD40 Ligand, a co-stimulatory molecule upstream of T-cell activation. Tacrolimus, the standard of care since 1994, is a calcineurin inhibitor that broadly dampens the entire immune system at a well-documented cost: nephrotoxicity that gradually destroys the very kidney it protects, plus diabetes, tremor, and hypertension.
When Tim Andrews received the first eGenesis pig kidney at MGH in January, his immunosuppression protocol included tegoprubart at 20 mg/kg alongside rituximab, antithymocyte globulin, ravulizumab, and standard-dose tacrolimus. Tegoprubart was not an afterthought but a cornerstone of the regimen.
74 vs. 61: A Number Worth Understanding
Estimated glomerular filtration rate, or eGFR, measures how well a kidney filters blood, with normal function above 90, Stage 3 chronic kidney disease below 60, and dialysis territory below 15.
In the BESTOW extension trial, kidney transplant recipients on tegoprubart had a mean eGFR of 74 mL/min/1.73 m² at 18 months. Those on tacrolimus: 61. A statistically significant 13-point gap (p<0.05) that widened over time. In the smaller Phase 1b cohort, eGFR on tegoprubart actually increased from 67 at 12 months to 74.2 at 24 months, the opposite of normal post-transplant trajectory, where kidney function declines as tacrolimus accumulates its nephrotoxic toll.
Put differently: at 18 months, tegoprubart patients had near-normal kidney function (Stage 2 CKD). Tacrolimus patients were drifting toward the Stage 3a boundary. If the BESTOW pattern holds through Phase 3, a sustained 13-point eGFR advantage at 18 months could translate into meaningfully longer graft survival.
After six months, zero tegoprubart patients experienced biopsy-proven acute rejection. Zero. In the tacrolimus arm, 64% of all rejection events occurred after the six-month mark, including two after 12 months. Side effects diverged just as sharply: headache 2% vs 12%, extremity pain 0% vs 10%, acute kidney injury 2% vs 6%.
$8.9 Billion, Burning Quietly
According to the National Kidney Foundation, roughly 90,000 Americans are currently on the kidney transplant waiting list. Annual dialysis costs in the United States run approximately $99,369 per patient, per the National Kidney Registry's 2024 analysis. Multiply those numbers: $8.94 billion per year spent keeping waitlisted patients alive while they wait for an organ that, statistically, most will never receive.
About 27,000 kidney transplants are performed annually in the US, but new listings add roughly 40,000 patients per year, so the list grows by about 13,000 names annually, and five-year mortality on dialysis exceeds 50%, with first-year mortality alone at 18.1%.
Transplantation inverts these economics with striking speed. In a propensity-matched Swedish cohort study, post-transplant healthcare costs averaged €57,278 ($62,000) in year one, then dropped to €11,513 ($12,500) in year two and stayed there, meaning even accounting for surgical costs, a transplant breaks even against dialysis within two years and every additional year of graft survival saves roughly $85,000.
If pig kidneys could clear the existing waitlist, replacing $99,369/year in dialysis with $15,000/year in post-transplant maintenance, the system saves approximately $7.6 billion annually. Even at an estimated $150,000 per xenotransplant procedure (extrapolating from current human kidney transplant costs), the 90,000-patient backlog would cost $13.5 billion to clear, a sum that pays for itself in under two years.
What Still Has to Go Right
Anyone who reads the preceding math and concludes that the kidney shortage is solved has not read enough transplant literature.
Start with survival. Tim Andrews's pig kidney lasted 271 days before function declined and the organ was removed. That is a record. But the median human donor kidney lasts 12 to 15 years, and crossing from 271 days to 12 years is not an incremental step. It is a different category of biological achievement, and no amount of gene editing or tegoprubart dosing has demonstrated anything close to it yet. Total living human recipients of gene-edited pig kidneys worldwide: four.
BESTOW, critically, studied human-to-human kidney transplants rather than xenotransplants. Tegoprubart's Phase 2 eGFR data tells us it is likely superior to tacrolimus for conventional transplants, but whether it can tame the far more aggressive immune response provoked by a pig organ is a separate and fundamentally unanswered question.
Scale presents its own cliff. eGenesis uses Yucatan miniature pigs cloned to maintain 69 edits with perfect fidelity, and cloning is slow, expensive, and difficult to industrialize, which means breeding from cloned founders helps but quality control for 69 simultaneous genomic modifications across thousands of production animals is a manufacturing problem that nobody in the field has solved, or even seriously attempted at production scale. Phase 3 enrollment for BESTOW is planned for late 2026. eGenesis's Phase 1/2/3 trial for EGEN-2784 has FDA clearance but has not yet published enrollment numbers.
And tegoprubart itself is unproven at the regulatory level that matters: Eledon is a small-cap biotech (Nasdaq: ELDN) with no approved products, and Phase 3 non-inferiority trials against tacrolimus are the next gate where most novel immunosuppressants have historically failed.
What We Actually Know
One pair of transgenes, TNFAIP3 and HMOX1, now has peer-reviewed evidence of superiority over other combinations in prolonging pig kidney survival. One targeted antibody has Phase 2 data showing statistically significant kidney function advantage and a dramatically cleaner side-effect profile, with zero rejections after the sixth month. Both are already being used in the same operating room, in the same patients, in the same protocol.
Ninety thousand Americans are on dialysis waiting for a kidney, and every year roughly 5,000 of them die on the list before an organ arrives. If the convergence of engineered organs and precision immunosuppression can push pig kidney survival from months to years, the waitlist stops being a queue and becomes an artifact of a problem that was solved.
Whether that happens in five years or fifteen, the two disciplines most likely to get there just demonstrated, independently and within the same week, that they are accelerating in the same direction.